Dependence on OviTex product family
Most revenue has come from a small number of reinforced tissue matrix products, so demand weakness would have an outsized effect.
- Scope
- OviTex and OviTex PRS
- Materiality
- high
TELA Bio, Inc.
TELA Bio, Inc. develops and commercializes biologic and synthetic surgical implant products used to reinforce soft tissue in hernia repair and plastic/reconstructive surgery. The company sells primarily in the United States through a direct sales force, with additional commercial activity in parts of Europe.
−41,3 %
67,7 %
−48,4 %
+15,8 %
4.20
3.59
| % | |
|---|---|
| OviTex | 75% Reinforced tissue matrix products used in hernia and soft-tissue repair procedures. |
| OviTex PRS | 20% Reinforced tissue matrix products used in plastic and reconstructive surgery. |
| OviTex IHR | 3% A configuration of the OviTex platform used in specific hernia repair applications. |
| Other product and distribution offerings | 2% Complementary surgical and wound-care related products distributed through partnerships. |
TELA Bio sells mainly to hospital accounts, where surgeons and purchasing teams decide which implant products are...
- U.S. hospital accountsprimary
Primary buyers that purchase OviTex and OviTex PRS for use in surgical procedures and inventory stocking.
- Surgeons and procedural usersprimary
Clinical users who select the products for hernia, plastic, and reconstructive surgery.
- Group purchasing organizationssecondary
Contracting intermediaries that improve access to hospital accounts and standardize purchasing.
- Integrated delivery networkssecondary
Health-system buyers that can broaden access across multiple hospitals and facilities.
- European hospital and distributor channelsemerging
Smaller non-U.S. customers reached through sales representatives, contractors, and distributors.
TELA Bio generates the vast majority of its revenue in the United States, where it maintains a direct sales force and...
- •U.S. is the core market and main revenue source
- •76 U.S. sales territories support hospital penetration
- •15 European sales territories extend the platform abroad
- •UK and EU activity is smaller and more distributor-supported
- •GPO and IDN coverage is important to U.S. access
TELA Bio is focused on expanding adoption of its OviTex platform by increasing hospital penetration, broadening...
01
Deepen adoption within existing hospital accountsshort-term
More procedures per account can raise utilization without relying only on new customer wins.
02
Expand commercial access through GPOs and IDNsshort-term
Contract coverage can improve hospital access and reduce friction in purchasing decisions.
03
Advance product development within the OviTex platformmedium-term
New configurations and enhancements can extend the product line and support broader clinical use.
04
Broaden the soft-tissue reconstruction portfoliomedium-term
Adjacent technologies can diversify revenue sources and reduce dependence on a single product family.
TELA Bio depends heavily on hospital adoption of a limited product family, so slower procedure growth or weaker...
Hospital adoption and purchasing cycle risk
Sales depend on surgeon preference, hospital contracting, and stocking decisions that can take time to convert.
- Scope
- U.S. hospital accounts
- Materiality
- high
Supplier and license dependence
OviTex products are sourced under a license arrangement with Aroa, creating reliance on third-party economics and terms.
- Scope
- Aroa license and transfer-cost structure
- Materiality
- high
Macroeconomic and procedure-volume pressure
Lower elective procedure activity or tighter hospital budgets can slow utilization and new account growth.
- Scope
- Surgical procedure demand
- Materiality
- medium
Inventory excess and obsolescence
If volume growth lags, the company may need to record additional excess and obsolete inventory charges.
- Scope
- Finished goods and consignment inventory
- Materiality
- medium
Leverage and refinancing risk
Debt maturities and interest obligations can constrain capital allocation and increase sensitivity to operating performance.
- Scope
- Credit facilities
- Materiality
- high
Revenue recognition on shipment vs surgical use
Point-in-time recognition with consignment exceptions
Consignment inventory accounting
Inventory and revenue timing
Excess and obsolete inventory reserves
Cost of revenue and inventory valuation
Aroa license transfer-cost and royalty accounting
Cost of revenue
Debt financing costs and interest expense
Interest expense and non-cash charges
INTEGRA LIFESCIENCES HOLDINGS CORP
IART · Surgical & Medical Instruments & Apparatus
MIMEDX GROUP, INC.
MDXG · Surgical & Medical Instruments & Apparatus
MIMEDX Group develops and commercializes regenerative biologic products used by clinicians to treat chronic wounds, burns, and surgical applications.
KALA BIO, Inc.
KALA · Pharmaceutical Preparations
TELEFLEX INC
TFX · Surgical & Medical Instruments & Apparatus
Sanara MedTech Inc.
SMTI · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Organogenesis Holdings Inc.
ORGO · Pharmaceutical Preparations
: 29/04/2026